WO2003097070A1 - Composition pharmaceutique comportant un corticosteroide et un antiseptique - Google Patents

Composition pharmaceutique comportant un corticosteroide et un antiseptique Download PDF

Info

Publication number
WO2003097070A1
WO2003097070A1 PCT/TR2003/000036 TR0300036W WO03097070A1 WO 2003097070 A1 WO2003097070 A1 WO 2003097070A1 TR 0300036 W TR0300036 W TR 0300036W WO 03097070 A1 WO03097070 A1 WO 03097070A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
antiseptic
mometasone furoate
triclosan
use according
Prior art date
Application number
PCT/TR2003/000036
Other languages
English (en)
Inventor
Orhan Vaizoglu
Original Assignee
Orva Ilaç Sanayi Ve Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orva Ilaç Sanayi Ve Ticaret A.S. filed Critical Orva Ilaç Sanayi Ve Ticaret A.S.
Priority to AU2003222565A priority Critical patent/AU2003222565A1/en
Publication of WO2003097070A1 publication Critical patent/WO2003097070A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Definitions

  • This invention relates to a composition for treating atopic dermatitis and infected eczema.
  • Atopic dermatitis is a common skin disorder in which the skin is red and shows features such as inflation, vesicles and pruritus.
  • Atopic dermatitis is characterized by clinically long - term survival, recurrent and severe itching eczema.
  • Atopic dermatitis predominantly affects in childhood and does not persist into adulthood .
  • Eczema is most often localized on the face of infants, on the extremities of children, and on the neck, flexures of elbows and of knees at all ages. Especially in children impetigo may develop after a secondary bacterial infection caused by staphylococcus aureus.
  • topical corticosteroids in particular high potency steroids such as betamethasone - 17 - valerate
  • a powerful antibiotic such as, for example, neomy ⁇ n, or fusidic acid
  • topical neomycin and fusidic acid are known to cause hypersensitivity.
  • the use of such strong combination therapies is undesirable. Accordingly, in the treatment of atopic dermatitis the need for developing a pharmaceutical composition which do not involve an antibiotic is required.
  • the European Patent EP 0752247 Bl discloses the use of a low potency corticosteroid together with an antiseptic in the formulation of a pharmaceutical composition for the treatment of atopic eczema. It is claimed that due to not containing an antibiotic this composition removes the disadvantages mentioned herein above, and that the use of an antiseptic results in an enhanced activity in combating atopic eczema.
  • the European Patent EP 0752247 Bl the use of a low potency corticosteroid limits the efficacy of the therapy in treating atopic dermatitis.
  • This composition may be applied to affected region at regular intervals of, for example, 1 - 4 times a day.
  • the use of a high potency corticosteroid in the treatment of atopic dermatitis is already known.
  • the United States Patent US 4472393 discloses the invention that defines the component mometasone furoate and the pharmaceutical composition containing this component.
  • the United States Patent US 4808610 discloses the anti-inflammatory cream composition including mometasone furoate.
  • This present invention defines the pharmaceutical composition comprising the combination of mometasone furoate, a high potency corticosteroid, and an antiseptic, preferably triclosan.
  • an antiseptic preferably triclosan.
  • the use of triclosan together with mometasone furoate in the treatment of atopic dermatitis and infected eczema is known to be more effective than the combinations defined in the previous technique.
  • the pharmaceutical composition which includes a high potency corticosteroid and an antiseptic, relieves the symptoms that occurs along with pruritus and inflammation in dermatitis responsive to the topical corticosteroid treatment.
  • the pharmaceutical composition that is used in the treatment of atopic dermatitis and infected eczema consists 0.01 to 5 percent mometasone furoate and 0.1 to 5 percent triclosan.
  • the pharmaceutical composition which is used in the treatment of atopic dermatitis and infected eczema, includes white petrolatum, white wax, propylene glycol stearate, promuigen, water, hexylene glycol, aluminum starch octenylsuccinate and titanium dioxide as excipients, other than the mometasone furoate and triclosan combination.
  • the process method of this pharmaceutical composition follows the steps herein below:
  • the pharmaceutical composition comprising the mometasone furoate and triclosan combination may also include white petrolatum, white wax, propylene glycol stearate, hexylene glycol and water as excipients. Firstly the white petrolatum, white wax, propylene glycol stearate are heated together to 70 degree. C, triclosan is added and the mixture is homogenized. Then the mometasone furoate, hexylene glycol and water is heated to 70. degree. C. and are added to the previously prepared mixture. And are homogenized.
  • the pharmaceutical composition including mometasone furoate and triclosan combination may be formulated into a preparation suitable for topical administration in a conventional manner.
  • types of preparation include oil / water emulsion (cream), solution, gels, lotion or ointment.
  • the formulation is eligible to be applied as a thin layer once a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pharmaceutique contenant une combinaison du corticostéroïde à puissance très élevée furoate de mometasone et un antiseptique. Ladite composition soulage les symptômes qui accompagnent le prurit et l'inflammation dans les dermatites répondant au traitement topique par les corticostéroïdes.
PCT/TR2003/000036 2002-05-17 2003-05-08 Composition pharmaceutique comportant un corticosteroide et un antiseptique WO2003097070A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003222565A AU2003222565A1 (en) 2002-05-17 2003-05-08 The pharmaceutical composition comprising a corticosteroid and an antiseptic

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2002/01343A TR200201343A2 (tr) 2002-05-17 2002-05-17 Kortikosteroid ve antiseptik içeren farmasötik bileşim
TR2002/01343 2002-05-17

Publications (1)

Publication Number Publication Date
WO2003097070A1 true WO2003097070A1 (fr) 2003-11-27

Family

ID=29546700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2003/000036 WO2003097070A1 (fr) 2002-05-17 2003-05-08 Composition pharmaceutique comportant un corticosteroide et un antiseptique

Country Status (3)

Country Link
AU (1) AU2003222565A1 (fr)
TR (1) TR200201343A2 (fr)
WO (1) WO2003097070A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063493A2 (fr) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Composition pharmaceutique topique pour la combinaison de l'acide fusidique avec un corticostéroïde
WO2010048675A1 (fr) * 2008-10-30 2010-05-06 Ego Pharmaceuticals Pty Ltd Compositions pharmaceutiques anti-inflammatoires comprenant un corticostéroïde, de l'hexylène glycol et de l'eau
WO2010130435A1 (fr) * 2009-05-12 2010-11-18 Galenica Ab Émulsion huile-dans-eau de mométasone
WO2010130428A1 (fr) * 2009-05-12 2010-11-18 Galenica Ab Émulsion d'huile dans l'eau de mométasone et de propylèneglycol
US9907807B2 (en) 2010-05-26 2018-03-06 Almirall, S.A. Topical pharmaceutical compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512987A (en) * 1982-07-15 1985-04-23 Ciba-Geigy Corporation New pharmaceutical preparations
EP0752247A1 (fr) * 1995-07-04 1997-01-08 Surtech International Ltd. Compositions contenant des corticostéroides et des phénols chlorés pour le traitement de l'exzème atopique
WO2001026658A2 (fr) * 1999-10-08 2001-04-19 Schering Corporation Traitement nasal topique
WO2002011711A2 (fr) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire
EP1205218A1 (fr) * 2000-11-14 2002-05-15 Benkert, Eugen Georg, Dr.med.dent. Antipsoriatrique topical comprenant de l'urée, un corticoide et un désinfectant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512987A (en) * 1982-07-15 1985-04-23 Ciba-Geigy Corporation New pharmaceutical preparations
EP0752247A1 (fr) * 1995-07-04 1997-01-08 Surtech International Ltd. Compositions contenant des corticostéroides et des phénols chlorés pour le traitement de l'exzème atopique
WO2001026658A2 (fr) * 1999-10-08 2001-04-19 Schering Corporation Traitement nasal topique
WO2002011711A2 (fr) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire
EP1205218A1 (fr) * 2000-11-14 2002-05-15 Benkert, Eugen Georg, Dr.med.dent. Antipsoriatrique topical comprenant de l'urée, un corticoide et un désinfectant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KALLIOMAEKI P ET AL: "EINE VERGLEICHENDE UNTERSUCHUNG UEBER DIE WIRKSAMBEIT UND VERTRAEGLICHKEIT DER CREMES CGP 433 UND GP 41'353 BEI DER BEHANDLUNG INFEKTIOESER DERMATITIDEN", H + G. ZEITSCHRIFT FUER HAUTKRANKHEITEN, GROSS VERLAG, BERLIN, DE, vol. 54, no. 14, 15 July 1979 (1979-07-15), pages 668 - 670, XP000602593, ISSN: 0301-0481 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063493A2 (fr) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Composition pharmaceutique topique pour la combinaison de l'acide fusidique avec un corticostéroïde
WO2009063493A3 (fr) * 2007-09-10 2009-10-22 Glenmark Pharmaceuticals Limited Composition pharmaceutique topique pour la combinaison de l'acide fusidique avec un corticostéroïde
RU2470645C2 (ru) * 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
WO2010048675A1 (fr) * 2008-10-30 2010-05-06 Ego Pharmaceuticals Pty Ltd Compositions pharmaceutiques anti-inflammatoires comprenant un corticostéroïde, de l'hexylène glycol et de l'eau
WO2010130435A1 (fr) * 2009-05-12 2010-11-18 Galenica Ab Émulsion huile-dans-eau de mométasone
WO2010130428A1 (fr) * 2009-05-12 2010-11-18 Galenica Ab Émulsion d'huile dans l'eau de mométasone et de propylèneglycol
CN102458382A (zh) * 2009-05-12 2012-05-16 咖勒尼卡公司 莫米松和丙二醇的水包油乳状液
US8728497B2 (en) 2009-05-12 2014-05-20 Galenica Ab Oil-in-water emulsion of mometasone and propylene glycol
CN102458382B (zh) * 2009-05-12 2015-03-18 咖勒尼卡公司 莫米松和丙二醇的水包油乳状液
EP2962688A1 (fr) * 2009-05-12 2016-01-06 Galenica AB Composition d'émulsion huile-dans-eau comportant du mométasone et du propylen glycol
US11395827B2 (en) 2009-05-12 2022-07-26 Galenica Ab Oil-in-water emulsion of mometasone and propylene glycol
US9907807B2 (en) 2010-05-26 2018-03-06 Almirall, S.A. Topical pharmaceutical compositions

Also Published As

Publication number Publication date
AU2003222565A1 (en) 2003-12-02
TR200201343A2 (tr) 2003-12-22

Similar Documents

Publication Publication Date Title
US9295644B2 (en) Methods and compositions for treating asthma
US4185100A (en) Topical anti-inflammatory drug therapy
US20040138179A1 (en) Antifungal formulations
DK2398457T3 (en) TOPICAL FORMULATION clobetasol propionate LOW DOSE FOR TREATMENT OF DISEASES skin and mucous membranes
JP2008502659A (ja) 乾癬の治療のための、クロベタゾールプロピオネートとカルシトリオールとを含む製薬組成物の使用
US8846646B2 (en) Topical treatment of skin infection
JPH02501739A (ja) ステロイドローション剤
US20030194446A1 (en) Zinc oxide compositions for dermatheraputics
JPH06128159A (ja) 外用剤
KR101642537B1 (ko) 푸시드산나트륨을 사용하고 생체중합체를 혼입한 약용 푸시드산 크림 및 이의 제조 방법
EP0908183A1 (fr) Déhydroépiandrostérone ou ses dérivés pour augmenter la quantité d'acide hyaluronique dans la peau
WO2003097070A1 (fr) Composition pharmaceutique comportant un corticosteroide et un antiseptique
US5707981A (en) Synergistic pharmaceutical compositions
CA1049409A (fr) Preparation a usage local contenant un steroide et de la neomycine
AU2003294027B2 (en) Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate
WO2007070423A2 (fr) Formulations de glucocorticosteroide locales
US5104657A (en) Combination preparations containing chloramphenicol, gentamicin and nystatin as active ingredients for the topical treatment of inflammatory skin disorders
AU2004281521B2 (en) Topical compositions comprising telmesteine for treating dermatological disorders
HU198841B (en) Process for producing composition suitable for treating psoriasis
Veien et al. Hydrocortisone 17-Butyrate (Locoid®) 0· 1% Cream versus Hydrocortisone (Uniderm®) 1% Cream in the Treatment of Children Suffering from Atopic Dermatitis
JPH09506897A (ja) 乾癬治療
WO2023119289A1 (fr) Formulations topiques pour la manipulation de la dermatite atopique
RU2223097C1 (ru) Комбинированное средство для лечения кожных заболеваний
WO1999045921A1 (fr) Traitement des coups de soleil
RU2223765C1 (ru) Противовоспалительный и антиаллергический состав

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP